herpes%20simplex%20virus%20infection
HERPES SIMPLEX VIRUS INFECTION
Primary herpes simplex virus (HSV) infection is first infection with either herpes simplex virus-1 (HSV-1) or herpes simplex virus-2 (HSV-2) in individuals who do not have antibodies to either HSV-1 or HSV-2.
First episode-non primary infection is infection with either HSV-1 or HSV-2 in individuals who have previously existing antibodies against HSV-1 or HSV-2 respectively.
Recurrent HSV infection results from reactivation of latent virus. It is usually brought about by triggering factors eg UV light, immunosuppression.
Orolabial HSV disease is mostly caused by HSV-1 that occurs most commonly in children <5 years of age. It is transmitted through close contact with individuals who have active viral shedding.
Genital HSV disease is caused by HSV-2 that is the usual cause of herpes genitalis. It typically occurs in adults and transmitted through sexual contact.

Principles of Therapy

Primary Herpes Simplex Virus (HSV) Infection

  • If given w/in 72 hours of symptom onset, antivirals can be effective in reducing severity & duration of symptoms; however, early treatment of primary infection does not prevent recurrences
  • Choice of agent depends on cost, dosing schedule & patient preference

Recurrent Genital Herpes Simplex Virus (HSV) Infection

  • Episodic treatment for recurrent genital HSV disease may be given as a single-day patient-initiated treatment or for 5 days
  • Long-term suppressive treatment (prophylaxis) for frequent recurrences of genital HSV disease requires at least 3 months to 1 year of therapy to achieve any efficacy

Pharmacotherapy

Symptomatic Therapy

Analgesics (Oral)

  • Eg Paracetamol, Ibuprofen
  • Symptomatic relief of pain

Anesthetics (Topical)

  • Eg Benzocaine, viscous Lidocaine, Dyclonine
  • Symptomatic relief of pain
  • In theory, may cause sensitization but rarely happens in practice
  • Various topical anesthetics are available. Please see prescribing information for specific formulations in the latest MIMS

Oral Preparations

  • Symptomatic relief of ulceration & inflammation in orolabial herpes simplex virys (HSV) disease

Zinc Preparations

  • Eg Zinc oxide/glycine cream, Zinc sulfate gel
  • Shorten time of resolution of symptoms


Antiviral Therapy - Oral

Aciclovir

  • Actions: Acyclic purine nucleoside analogue that is a competitive inhibitor of viral DNA polymerase
    • Limits viral replication & stops further spread of the virus to other cells
  • Effect: Oral & Intravenous (IV) are both effective in treating HSV-1 & HSV-2
    • IV is usually reserved for severe disease or complications where hospitalization is necessary

Famciclovir

  • Action: Famciclovir is a prodrug of Penciclovir
    • Famciclovir has higher bioavailability than Penciclovir & is rapidly converted to Penciclovir in gastrointestinal tract (GIT), blood & liver
    • Penciclovir has similar mechanism of action as Acyclovir
  • Effect: Efficacy is similar to Aciclovir & Valaciclovir

Valaciclovir

  • Action: L-valine ester prodrug of Aciclovir, rapidly metabolized to Aciclovir by liver & intestine
  • Effect: Same efficacy as Aciclovir

Foscarnet

  • Action: Pyrophosphate analogue that is a noncompetitive inhibitor of viral RNA & DNA polymerase
    • Foscarnet is virostatic & activation by thymidine kinase is not required
  • May be used for Aciclovir-resistant mucocutaneous HSV infections in immunocompromised patients

Methisoprinol or Inosiplex

  • Action: Antiviral activity by modifying or stimulating cell-mediated immune process

Antiviral Therapy - Topical

Aciclovir - Same as above

  • Topical agent has shown limited efficacy

Cidofovir

  • May be used for Aciclovir-resistant genital infections

Docosanol

  • Action: Inhibits fusion between the cell plasma membrane & HSV which prevents viral entry into cells & viral replication
  • Effect: Decreases healing time of recurrent herpes labialis

Penciclovir

  • Actions: Same mechanism of action as Aciclovir
  • Effect: Decreases healing time of recurrent herpes labialis

Tromantadine

  • Action: Derivative of Amantadine w/ antiviral activity
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Infectious Diseases - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
30 Nov 2017
Fluarex Tetra - Inactivated quadrivalent influenza vaccine (split virion) vaccine (inj) 0.5 mL - GlaxoSmithKline
02 Nov 2017
In this issue of MIMS Anti-Infective Supplement, we bring you clinical updates related to combating infectious diseases, and also a symposium highlight in conjunction with the launch of ceftolozane/tazobactam (Zerbaxa; Merck Sharp & Dohme Sdn Bhd) in Malaysia. 
30 Oct 2016
Close to a quarter of the world’s population (1.7 billion) were latently infected with Mycobacterium tuberculosis (M.tb) in 2014, according to estimates using mathematical modelling.
10 Sep 2016
More men than women are diagnosed with tuberculosis (TB) in low- and middle-income countries, according to a study. Furthermore, men are also less likely to get access to TB care in many settings.